来源:知识产权学术与实务研究网 作者:王迁 时间:2009-07-24 阅读数:
See J. Thomas McCarthy, McCarthy on Trademarks and Unfair Competition (4th ed.), West Publications (2004) § 25:18; Ciba-Geigy Corp. v. Bolar Pharmaceutical Co., 747 F.2d 844 (3rd Cir.1984) SK & F, Co. v. Premo Pharmaceutical Laboratories, Inc., 625 F.2d 1055 (3rd Cir.1980); Merrell-National Laboratories, Inc. v. Zenith Laboratories, Inc., 194 U.S.P.Q. 157 (D.N.J.1977).
[25]
See Rolex Watch USA, Inc., v. Robert Meece, 158 F.3d 816, at 822, 828-829 (5th Cir, 1998)
[26]
See Inwood Laboratories, Inc. v. Ives Laboratories, Inc., 456 U.S. 844 (1982)
[27]
See Restatement of the Law, Third, Unfair Competition § 27 (1995),
[28]
See Sealy, Inc. v. Easy Living, Inc. 743 F.2d 1378, at 1381 (9th Cir. 1984)
[29]
[30]
不仅如此,由于仿制药品在价格上远低于原专利药品,美国许多州都通过法律鼓励药店向消费者销售仿制药品。如纽约州的法律规定:药品处方上必须留有让医生签字说明是否允许使用仿制药品替代原专利药品的栏目。在医生签字允许的情况下,药剂师在征得患者同意后应当提供仿制药品,并说明药品的来源。See N. Y. Pub. Health Law § 206.1(o)
[31]
[32]
See Restatement of the Law, First, Tort § 741 (1938)
[33]
[34]
See Restatement of the Law, First, Tort § 741 (1938)
[35]
See William R. Warner & Company v. Eli Lilly & Company, 265 U.S. 526, 527-528 (1924)
[36]
[37]
See William R. Warner & Company v. Eli Lilly & Company, 265 U.S. 526, 527-528 (1924)
[38]
[39]
[40]
See SK&F, Co. v. Premo Pharmaceutical Laboratories, (3rd Cir )625 F.2d 1055, at 1057-1058 (1980)
[41]
[42]
[43]